Found 3 articles for: "immune checkpoint inhibitors"
Clinical Features and the Management of Drug-Induced Eruptive Keratoacanthoma and Squamous Cell Carcinoma: A Review of 172 Cases
May 2025 | Volume 24 | Issue 5 | Original Article | 476 | Copyright © May 2025
Background: The sudden appearance of keratoacanthomas (KA) and squamous cell carcinomas (SCC) is a serious complication of several oncologic and immunomodulatory medications. The...
Read MoreCutaneous Immune-Related Adverse Events Associated With Immunotherapy in Patients With Melanoma
May 2025 | Volume 24 | Issue 5 | Original Article | 490 | Copyright © May 2025
Background: Cutaneous immune-related adverse events (irCAEs) have been commonly reported as a consequence of immune checkpoint inhibitors (ICIs) for the treatment of advanced sta...
Read MoreAlopecia as an Adverse Event of Immune Checkpoint Inhibitor Therapies: Clinical Evidence and Outcomes
March 2025 | Volume 24 | Issue 3 | Original Article | 255 | Copyright © March 2025
Immunotherapy utilizing immune checkpoint inhibitors (ICIs) such as PD-1, PD-L1, and CTLA-4 inhibitors has revolutionized cancer therapy by enhancing T cell recognition and attack against cancer ...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.